Strong Results and Improved Guidance Lifted Artivion (AORT)

Core Insights - The Alger Weatherbie Specialized Growth Fund's Class A shares underperformed the Russell 2500 Growth Index in Q3 2025, despite the S&P 500 Index rising by 8.12% [1] Company Overview - Artivion, Inc. (NYSE:AORT) is a global manufacturer and distributor of medical devices and implantable human tissues, focusing on cardiac and vascular surgeries for patients with aortic disease [3] - The company reported total revenues of $113 million for Q2 2025, marking an increase of over 14% compared to Q2 2024 [4] Stock Performance - Artivion, Inc. experienced a one-month return of 6.90% and a significant 69.32% increase in share value over the last 52 weeks, closing at $45.26 per share on October 28, 2025, with a market capitalization of $2.136 billion [2] Fund Performance and Holdings - The Alger Weatherbie Specialized Growth Fund highlighted Artivion, Inc. as a positive contributor during the quarter, driven by strong fiscal second-quarter earnings and an improved full-year outlook [3] - The fund's top five holdings can provide insights into its best investment picks for 2025 [1]